摘要
目的探讨阿托伐他汀对高血压合并2型糖尿病患者血浆高敏C-反应蛋白（hsCRP）和颈动脉粥样硬化的影响和机制。方法测定40例高血压合并2型糖尿病患者在常规治疗基础上加服阿托伐他汀（10mg／d）治疗前及治疗6个月后血浆hsCRP浓度、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）及经彩色多普勒技术测定颈动脉内膜中层厚度（IMT）。常规治疗组40例为对照组。结果阿托伐他汀治疗6个月后颈动脉IMT值缩小，血中TC、TG、LDL-C、hsCRP水平降低（P〈0．05），另一组变化差异无统计学意义（P〉0．05）。结论阿托伐他汀治疗可改善高血压合并2型糖尿病患者颈动脉粥样硬化程度，并有稳定斑块作用。
Objective To explore the effect of atorvastetin on hsCRP and carotid atherosclerosis in hypertensive patients complicated with type 2 diabetes mellitus. Methods 40 hypertensive patients complicated with type 2 diabetes mellitus were received atorvastetin （10 mg/d） bisides conventional treatment, hsCRP, totle cholestrol （TC）, low density lipoprotein cholesterol and carotid intima-medial thickness （IMT） were measured before and after 6 months treatment in all patients. Another 40 hypertensive patients complicated with type 2 diabetes mellitus as controls. Results ITM, the TC, TG, LDL-C, hsCRP were all reduced after atorvastetin treatment （P〈0.05）, and the other group with conventional treatment had not significant disparity （P〉0.05）. Conclusion Atorvastatin improves the carotid arteriosclerosis and inflammatory reaction, promoting stabilization of atherosclerotic plaque in hypertensive patients complicated with type 2 diabetes mellitus.
出处
《中国实用医刊》
2008年第21期30-31,共2页
Chinese Journal of Practical Medicine
